{"id":79194,"date":"2026-09-07T12:34:07","date_gmt":"2026-09-07T04:34:07","guid":{"rendered":"https:\/\/flcube.com\/?p=79194"},"modified":"2026-09-07T12:34:08","modified_gmt":"2026-09-07T04:34:08","slug":"innovent-biologics-suzhou-base-passes-ema-on-site-inspection-securing-eu-gmp-certification-on-first-attempt","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=79194","title":{"rendered":"Innovent Biologics’ Suzhou Base Passes EMA On\u2011Site Inspection, Securing EU GMP Certification on First Attempt"},"content":{"rendered":"\n

Innovent Biologics<\/strong> (HKG: 1801<\/a>) announced that its Suzhou commercialization base successfully passed the on\u2011site Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA)<\/strong> on its first attempt and officially received EU GMP certification<\/strong>. The milestone validates the company’s high\u2011end biopharmaceutical manufacturing platform against one of the world’s most stringent regulatory standards.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Field<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>European Medicines Agency (EMA)<\/strong><\/td><\/tr>
Inspection Type<\/td>On\u2011site GMP inspection \u2014 passed on first attempt<\/td><\/tr>
Certification<\/td>EU GMP certification<\/strong> officially received<\/td><\/tr>
Site<\/td>Suzhou commercialization base, Innovent Biologics<\/strong> (HKG: 1801)<\/td><\/tr>
Compliance Standards<\/td>Built to NMPA<\/strong>, FDA<\/strong>, and EMA<\/strong> GMP standards<\/td><\/tr>
Date<\/td>07 Sep 2026<\/td><\/tr>
Next Steps<\/td>Supports global supply and commercialization of biologics from the Suzhou base<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Manufacturing Base Profile<\/h2>\n\n\n\n
Facility<\/th>Building Area<\/th>Production Capacity<\/th>Key Features<\/th><\/tr><\/thead>
Site 1<\/td>93,000 square meters<\/td>60,000 liters (antibody)<\/td>Includes an ADC<\/strong> manufacturing line<\/td><\/tr>
Site 2<\/td>176,000 square meters<\/td>80,000 liters (antibody)<\/td>Large\u2011scale antibody production<\/td><\/tr>
Total<\/td>\u2014<\/td>140,000 liters operational capacity<\/strong><\/td>~20% of China’s total biomanufacturing capacity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The Suzhou base has been constructed in compliance with NMPA<\/strong>, FDA<\/strong>, and EMA<\/strong> GMP standards, positioning it as a globally aligned commercialization platform. Site 1 pairs 60,000 liters of antibody production capacity with a dedicated ADC<\/strong> (antibody\u2011drug conjugate) manufacturing line, while Site 2 adds 80,000 liters of antibody capacity across 176,000 square meters of building area.<\/p>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n